N. Smith

发表

Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.

Andiliy G. Lai, B. Darimont, J. Sensintaffar, 2015, Bioorganic & medicinal chemistry letters.

Development of antiandrogen ARN-509 1 ARN-509 : a novel antiandrogen for prostate cancer treatment

E. Stanchina, H. Scher, V. Arora, 2012 .

Interactive influences of peroxisome proliferator-activated receptor α activation and glucocorticoids on pancreatic beta cell compensation in insulin resistance induced by dietary saturated fat in the rat

M. Holness, M. Sugden, G. Greenwood, 2005, Diabetologia.

Acute (24 h) activation of peroxisome proliferator-activated receptor-alpha (PPARalpha) reverses high-fat feeding-induced insulin hypersecretion in vivo and in perifused pancreatic islets.

M. Holness, M. Sugden, G. Greenwood, 2003, The Journal of endocrinology.

Excessive glucocorticoid exposure during late intrauterine development modulates the expression of cardiac uncoupling proteins in adult hypertensive male offspring

M. Langdown, M. Holness, M. Sugden, 2001, Pflügers Archiv.

Peroxisome Proliferator–Activated Receptor-α and Glucocorticoids Interactively Regulate Insulin Secretion During Pregnancy

M. Holness, M. Sugden, G. Greenwood, 2006, Diabetes.

Evaluation of the role of peroxisome-proliferator-activated receptor alpha in the regulation of cardiac pyruvate dehydrogenase kinase 4 protein expression in response to starvation, high-fat feeding and hyperthyroidism.

K. Bulmer, M. Holness, M. Sugden, 2002, The Biochemical journal.

PPAR (cid:1) activation reverses adverse effects induced by high-saturated-fat feeding on pancreatic (cid:2) -cell function in late pregnancy

M. Holness, M. Sugden, G. Greenwood, 2007 .

PPARα activation reverses adverse effects induced by high-saturated-fat feeding on pancreatic β-cell function in late pregnancy

M. Holness, M. Sugden, G. Greenwood, 2007 .

Acute omega-3 fatty acid enrichment selectively reverses high-saturated fat feeding-induced insulin hypersecretion but does not improve peripheral insulin resistance.

M. Holness, M. Sugden, G. Greenwood, 2004, Diabetes.

Investigation of potential mechanisms regulating protein expression of hepatic pyruvate dehydrogenase kinase isoforms 2 and 4 by fatty acids and thyroid hormone.

K. Bulmer, M. Holness, M. Sugden, 2003, The Biochemical journal.

Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft.

Andiliy G. Lai, B. Darimont, J. Sensintaffar, 2019, Bioorganic & medicinal chemistry letters.

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling

C. Hassig, J. Hager, M. Mapara, 2008, Molecular Cancer Therapeutics.

Development of anti-androgen ARN-509 1 ARN-509: a novel anti-androgen for prostate cancer treatment

H. Scher, V. Arora, C. Sawyers, 2012 .

Pharmacological Characterization of KLYP961, a Dual Inhibitor of Inducible and Neuronal Nitric-Oxide Synthases

Nahid M. Yazdani, T. Rao, A. Shiau, 2011, Journal of Pharmacology and Experimental Therapeutics.

Discovery of dual inducible/neuronal nitric oxide synthase (iNOS/nNOS) inhibitor development candidate 4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one (KD7332) part 2: identification of a novel, potent, and selective series of benzimidazole-quinolinone iNOS/nNOS

Nahid M. Yazdani, T. Rao, A. Shiau, 2010, Journal of medicinal chemistry.

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo

A. Saven, T. Rao, J. Malecha, 2008, Molecular Cancer Therapeutics.

Alpha-mercaptoketone based histone deacetylase inhibitors.

J. Malecha, T. Z. Hoffman, B. Wiley, 2008, Bioorganic & medicinal chemistry letters.

Identification of KD5170: a novel mercaptoketone-based histone deacetylase inhibitor.

T. Rao, J. Malecha, T. Z. Hoffman, 2008, Bioorganic & medicinal chemistry letters.

Efficacy and safety of sirolimus in a neonate with persistent hypoglycaemia following near-total pancreatectomy for hyperinsulinaemic hypoglycaemia

S. Ellard, T. Jones, E. Davis, 2015, Journal of pediatric endocrinology & metabolism : JPEM.

Diabetogenic impact of long-chain omega-3 fatty acids on pancreatic beta-cell function and the regulation of endogenous glucose production.

M. Holness, M. Sugden, G. Greenwood, 2003, Endocrinology.

Discovery of inducible nitric oxide synthase (iNOS) inhibitor development candidate KD7332, part 1: Identification of a novel, potent, and selective series of quinolinone iNOS dimerization inhibitors that are orally active in rodent pain models.

Nahid M. Yazdani, J. Walsh, T. Rao, 2009, Journal of medicinal chemistry.

Agents modificateurs de l'absorption du cholesterol cellulaire

D. Severance, N. Smith, Elisabeth M. M. Gardiner, 2006 .

Heteroaromatic-aminomethyl quinolones: potent and selective iNOS inhibitors.

Nahid M. Yazdani, T. Rao, A. Shiau, 2012, Bioorganic & medicinal chemistry letters.

Primate Spinothalamic Tract Neurons Nitric Oxide Mediates the Central Sensitization of

Nahid M. Yazdani, W. Willis, T. Symons, 2015 .

ARN-509: a novel antiandrogen for prostate cancer treatment.

H. Scher, V. Arora, C. Sawyers, 2012, Cancer research.

The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer

K. Walter, Andiliy G. Lai, J. Giltnane, 2016, eLife.

Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.

Andiliy G. Lai, B. Darimont, J. Sensintaffar, 2015, Journal of medicinal chemistry.

KD 5170 , a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo

A. Saven, T. Rao, J. Malecha, 2008 .

Hyperthyroidism impairs pancreatic beta cell adaptations to late pregnancy and maternal liporegulation in the rat

M. Holness, M. Sugden, G. Greenwood, 2005, Diabetologia.

A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.

M. Bashir, E. Lawitz, S. Harrison, 2021, Journal of hepatology.

Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.

Andiliy G. Lai, B. Darimont, J. Sensintaffar, 2018, ACS medicinal chemistry letters.

Diabetogenic Impact of Long-Chain ω-3 Fatty Acids on Pancreatic β-Cell Function and the Regulation of Endogenous Glucose Production

M. Holness, M. Sugden, G. Greenwood, 2003 .

Peroxisome proliferator-activated receptor-alpha activation during pregnancy attenuates glucose-stimulated insulin hypersecretion in vivo by increasing insulin sensitivity, without impairing pregnancy-induced increases in beta-cell glucose sensing and responsiveness.

M. Holness, M. Sugden, G. Greenwood, 2003, Endocrinology.

Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.

Andiliy G. Lai, B. Darimont, J. Sensintaffar, 2018, Journal of medicinal chemistry.

PPARalpha activation and increased dietary lipid oppose thyroid hormone signaling and rescue impaired glucose-stimulated insulin secretion in hyperthyroidism.

M. Holness, M. Sugden, G. Greenwood, 2008, American journal of physiology. Endocrinology and metabolism.

Abstract 1648: Discovery and evolution of orally bioavailable selective estrogen receptor degraders for ER+ breast cancer: From GDC-0810 to GDC-0927

Jun Liang, A. Daemen, Andiliy G. Lai, 2018, Cancer Chemistry.

Nahid M. Yazdani, T. Rao, A. Shiau, 2010, Journal of medicinal chemistry.

KLYP956 Is a Non-Imidazole-Based Orally Active Inhibitor of Nitric-Oxide Synthase Dimerization

T. Rao, A. Shiau, C. Hassig, 2009, Molecular Pharmacology.